Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Prioritisation and Risk Evaluation of Medicines in the EnviRonment

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

API prioritisation and selection for iterative assessment (D1.2.1) (si apre in una nuova finestra)

This report describes the selection process of approximately 15 APIs that will be tested in WP1.3 because of a lack of data to conclude on the potential for environmental risk. This includes a description of the original API list considered, the decision tree(s) used for prioritisation, the prioritisation results, the criteria used for API selection, and the ultimate results of the selection process.

Determine bioavailability, metabolism and biological effects of MPA in fish (D2.2.5) (si apre in una nuova finestra)

Uptake will be measured using rainbow trout gill cell assay; bioavailability will be quantified via blood plasma protein binding measurements in trout and fathead minnow; metabolism will be measured using trout hepatocyte assay; developmental toxicity will be measured using the ZEDTA assay; immunotoxicity will be measured using transgenic zebrafish to track B and T cells, neutrophils and macrophages.

Report on stakeholder questions and requirements and work plan for further guidance development (D4.1.1) (si apre in una nuova finestra)

Report on the stakeholder questions and requirements, as identified during interviews and web-based questionnaire, the results of the workshop, the identified possible guidance products and the work plan for further guidance development.

A report describing the feasibility of greener drug design (D4.2.4) (si apre in una nuova finestra)

Consensus document that determines whether greener drug design is feasible and how it can be realised if the potential exists.

Report summarising drug discovery and development process and key attributes of tools/models (D4.2.1) (si apre in una nuova finestra)

Report highlighting a clear understanding where environmental hazard and risk are currently considered in the drug development process and where future potential exists for earlier integration of these considerations together with the attributes required for environmental screening tools/ models.

Evaluation of fish gill uptake and hepatic clearance for 10-20 APIs, including feasibility of the OECD 319b test or organ-chips for prediction of in vivo hepatic clearance of APIs in fish (D2.3.1) (si apre in una nuova finestra)

Assessment of the API uptake (bioavailability) and clearance of selected APIs in a primary 3D rainbow trout gill cell culture assay system and an analyses on the hepatic clearance of selected APIs through the use of (i) a primary 3D rainbow trout liver cell culture assay and (ii) a rainbow trout subcellular S9 fraction.

List of approximately 10 APIs selected for MoA-driven testing in WP1.3 (D1.1.2) (si apre in una nuova finestra)

This report describes the selection process of approximately 10 APIs that will be tested in WP1.3 because of a lack of ecotoxicity data on their specific Mode of Action. This includes a description of how the universe of APIs was compiled, the decision tree(s), the prioritisation results, the criteria used for API selection and the final results.

Mechanistic understanding on the potential for targeted pharmacological responses to mediate chronic effect outcomes from the application of transgenic zebrafish models (D2.3.3) (si apre in una nuova finestra)

Physiological/functional outcomes for selected APIs with specific pharmacological target activation prioritised in WP2.2 will be investigated using transgenic reporter zebrafish. The resulting data will be made available for use in the iterative assessment in WP1.2.

Project communication plan and initial toolset (si apre in una nuova finestra)

A plan for dissemination that includes the communication objectives, target audiences, activities to be carried out and tools that will support their implementation, with connections among these components. It will also include an initial set of communication materials.

Initial Data and Knowledge Management plan (D3.3.2) (si apre in una nuova finestra)

Outline for the PREMIER data and knowledge management policy.

Guidance for first set of selected stakeholder questions and requirements (D4.1.2) (si apre in una nuova finestra)

A first guidance document based on the main priorities identified in D4.1.1.

Machine-learning based models for estimating sorption in sludge, sediment, soil and sorbents used in treatment (D2.1.2) (si apre in una nuova finestra)

Report describing the generalized model for estimating sorption behaviour in sludge, soil, sediment and sorbents used in treatment processes.

Evaluation of the risk for bio-accumulation of APIs in fish via irreversible inhibition of hepatic CYPs (D2.3.2) (si apre in una nuova finestra)

The ability of selected APIs to irreversibly inhibit CYP enzyme activity will be quantified (IC50 shift) using rainbow trout RT-S9 and well-plate technologies.

Summary report describing fundamental drug design principles and their environmental significance (D4.2.2) (si apre in una nuova finestra)

onsensus document that describes industry-wide principles used to design safe and efficacious medicines.

Inventory of APIs on the European market together with important ecotox, phys/chem and consumption data (D1.1.1) (si apre in una nuova finestra)

All known APIs in use in Europe have been entered into the PREMIER database in collaboration with WP3.1. Additionally, data on name(s), CAS-No, IUPAC International Chemical Identifier (InChI), ATC classification, therapeutic plasma concentration, defined daily doses, usage, therapeutic MoA, physico-chemical properties and ecotoxicity, as far as available at this point in time, have been added to the PREMIER database.

PREMIER ERA database architecture agreed and established (D3.1.1) (si apre in una nuova finestra)

An initial structure of the database will be agreed between partners to capture APIs authorised for use in Europe and facilitate the upload of existing environmental data.

Integration of existing GLP study data from industry partners and EPAR data (D3.1.3) (si apre in una nuova finestra)

Existing GLP study data from industry partners and EPAR data from the EMA website will be uploaded using agreed templates and used to populate the PREMIER database. The templates will be designed specifically for each study so that they enable summary reports to be generated that meet the need of the wider stakeholder community.

Pubblicazioni

GREENER Pharmaceuticals for More Sustainable Healthcare (si apre in una nuova finestra)

Autori: Caroline T. A. Moermond, Neele Puhlmann, A. Ross Brown, Stewart F. Owen, Jim Ryan, Jason Snape, Bastiaan J. Venhuis, and Klaus Kümmerer
Pubblicato in: Environmental Science and Technology Letters, Numero 23288930, 2022, ISSN 2328-8930
Editore: ACS (American Chemical Society) Publications
DOI: 10.1021/acs.estlett.2c00446

Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment? (si apre in una nuova finestra)

Autori: F.D. Spilsbury, P.A. Inostroza, P. Svedberg, C. Cannata, A.M.J. Ragas, T. Backhaus
Pubblicato in: Water Research, 2023, Pagina/e 121002, ISSN 0043-1354
Editore: Elsevier BV
DOI: 10.1016/j.watres.2023.121002

Systematic Handling of Environmental Fate Data for Model Development─Illustrated for the Case of Biodegradation Half-Life Data (si apre in una nuova finestra)

Autori: Jasmin Hafner, Kathrin Fenner, and Andreas Scheidegger
Pubblicato in: Environmental Science & Technology Letters, 2023, ISSN 0000-0000
Editore: Environmental Science & Technology Letters
DOI: 10.1021/acs.estlett.3c00526

Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout (Oncorhynchus mykiss) liver S9 fractions (si apre in una nuova finestra)

Autori: Tea Pihlaja, Timo Oksanen, Netta Vinkvist, Tiina Sikanen
Pubblicato in: Frontiers in Toxicology, Numero 6, 2024, ISSN 2673-3080
Editore: Frontiers in Toxicology
DOI: 10.3389/ftox.2024.1406942

Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment (si apre in una nuova finestra)

Autori: Cristiana Cannata, Thomas Backhaus, Irene Bramke, Maria Caraman, Anna Lombardo, Rhys Whomsley, Caroline T.A. Moermond, Ad M.J. Ragas
Pubblicato in: Environment International, Numero 183, 2024, Pagina/e 108379, ISSN 0160-4120
Editore: Pergamon Press Ltd.
DOI: 10.1016/j.envint.2023.108379

Combining predictive and analytical methods to elucidate pharmaceutical biotransformation in activated sludge (si apre in una nuova finestra)

Autori: Leo Trostel, Claudia Coll, Kathrin Fenner, and Jasmin Hafner
Pubblicato in: Environmental Science: Processes & Impacts, 2023, ISSN 0000-0000
Editore: Environmental Science: Processes & Impacts
DOI: 10.1039/d3em00161j

Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact (si apre in una nuova finestra)

Autori: Rodrigo Vidaurre, Irene Bramke, Neele Puhlmann, Stewart F. Owen, Daniela Angst, Caroline Moermond, Bastiaan Venhuis, Anna Lombardo, Klaus Kümmerer, Tiina Sikanen, Jim Ryan, Andreas Häner, Gemma Janer, Silvio Roggo, Alison Nimrod Perkins
Pubblicato in: Drug Discovery Today, Numero 29, 2024, Pagina/e 104022, ISSN 1359-6446
Editore: Elsevier BV
DOI: 10.1016/j.drudis.2024.104022

Minimizing Experimental Testing on Fish for Legacy Pharmaceuticals (si apre in una nuova finestra)

Autori: Anja Coors, A. Ross Brown, Samual K Maynard, Alison Nimrod Perkins, Stewart Owen, Charles R Tyler
Pubblicato in: ACS publications, 2023, ISSN 0000-0000
Editore: American Chemical Society
DOI: 10.1021/acs.est.2c07222

Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and development (si apre in una nuova finestra)

Autori: Neele Puhlmann, Rodrigo Vidaurre, Klaus Kümmerer
Pubblicato in: European Journal of Pharmaceutical Sciences, Numero Volume 192, 1 January 2024, 106614, 2023, ISSN 0928-0987
Editore: Elsevier BV
DOI: 10.1016/j.ejps.2023.106614

A Generalized Physiologically Based Kinetic Model for Fish for Environmental Risk Assessment of Pharmaceuticals (si apre in una nuova finestra)

Autori: Jiaqi Wang, Tom M. Nolte, Stewart F. Owen, Rémy Beaudouin, A. Jan Hendriks, and Ad M.J. Ragas
Pubblicato in: Environmental Science & Technology, Numero 0013936X, 2022, ISSN 0013-936X
Editore: American Chemical Society
DOI: 10.1021/acs.est.1c08068

The VERA software: Implementation of the acute fish toxicity endpoint and its application to pharmaceutical compounds (si apre in una nuova finestra)

Autori: Erika Colombo, Edoardo Luca Viganò, Giuseppa Raitano, Anna Lombardo, Alberto Manganaro, Alessio Sommovigo, Emilio Benfenati
Pubblicato in: Chemosphere, Numero 358, 2024, Pagina/e 142232, ISSN 0045-6535
Editore: Pergamon Press Ltd.
DOI: 10.1016/j.chemosphere.2024.142232

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals (si apre in una nuova finestra)

Autori: Chrisna Matthee, Andrew Ross Brown, Anke Lange, and Charles R. Tyler
Pubblicato in: Environmental Science & Technology, 2023
Editore: ACS Publications
DOI: 10.1021/acs.est.2c09576

È in corso la ricerca di dati su OpenAIRE...

Si è verificato un errore durante la ricerca dei dati su OpenAIRE

Nessun risultato disponibile

Il mio fascicolo 0 0